Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD1: ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06586112Phase 3Completed
- Sponsor
- Alumis Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of envudeucitinib in plaque psoriasis, sponsored by Alumis Inc.. Started Jul 2024; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06586112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586112.